The role of paclitaxel in the treatment of head and neck cancer

Details

Serval ID
serval:BIB_BB5C36C96C21
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The role of paclitaxel in the treatment of head and neck cancer
Journal
Seminars in Oncology
Author(s)
Vokes  E. E., Haraf  D. J., Stenson  K., Stupp  R., Malone  D., Levin  J., Weichselbaum  R. R.
ISSN
0093-7754 (Print)
Publication state
Published
Issued date
10/1995
Volume
22
Number
5 Suppl 12
Pages
8-12
Notes
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review --- Old month value: Oct
Abstract
Current chemotherapeutic approaches to recurrent head and neck cancer have routinely yielded response rates of 10% to 30% (for single agents) and 30% to 50% (for combination chemotherapy). However, median survival times for patients with metastatic and/or recurrent disease have stagnated at around 6 months since the 1970s. The investigation of new drugs and treatment approaches thus continues to be a high priority. One such agent, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), has shown good single-agent activity and is also believed to potentiate the effects of radiation therapy in patients with head and neck cancer. We have focused on the addition of paclitaxel to the previously established combination of 5-fluorouracil, hydroxyurea, and radiation therapy. The study goals are to establish the maximum tolerated dose and dose-limiting toxicity of paclitaxel when added to this combination as a 5-day continuous infusion on a biweekly schedule. Preliminary results of this ongoing study have demonstrated activity in patients with poor-prognosis head and neck cancer. Major dose-limiting toxicities have consisted of neutropenia and mucositis, and definition of a recommended phase II dose is in progress.
Keywords
Adult Aged Aged, 80 and over Animals Antineoplastic Agents, Phytogenic/*therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carboplatin/administration & dosage Cisplatin/administration & dosage Female Fluorouracil/administration & dosage Granulocyte Colony-Stimulating Factor/administration & dosage Head and Neck Neoplasms/*drug therapy/radiotherapy Humans Hydroxyurea/administration & dosage Male Middle Aged Neoplasm Recurrence, Local/drug therapy Paclitaxel/adverse effects/*therapeutic use Radiotherapy, Adjuvant Tumor Cells, Cultured
Pubmed
Web of science
Create date
28/01/2008 8:39
Last modification date
20/08/2019 15:29
Usage data